These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8094219)

  • 1. Absence of hepatitis A after treatment with pasteurised factor VIII concentrates in children with haemophilia A and von Willebrand disease.
    Kreuz W; Klarmann D; Auerswald G; Auberger K; Gürtler L; Rabenau H; Doerr WD
    Lancet; 1993 Feb; 341(8842):446. PubMed ID: 8094219
    [No Abstract]   [Full Text] [Related]  

  • 2. Human plasma von Willebrand factor/factor VIII complex (Haemate P/Humate-P) in von Willebrand disease and haemophilia A: a viewpoint by Eric Berntorp.
    Berntorp E
    Drugs; 2007; 67(10):1520. PubMed ID: 17600396
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of plasma and/or factor VIII concentrates administration on platelet functions in patients with haemophilia A and von Willebrand's disease (author's transl)].
    Gamba G; Grignani G; Nicolini E; Ascari E
    Haematologica; 1975 Jun; 60(2):168-83. PubMed ID: 808449
    [No Abstract]   [Full Text] [Related]  

  • 4. Human plasma von Willebrand factor/factor VIII complex (Haemate P/Humate-P): in von Willebrand disease and haemophilia A.
    Carter NJ; Scott LJ
    Drugs; 2007; 67(10):1513-9. PubMed ID: 17600395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haemophilia care within the United Kingdom.
    Ludlam CA
    Haemophilia; 1998 Jul; 4(4):427-8. PubMed ID: 9873769
    [No Abstract]   [Full Text] [Related]  

  • 6. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune status of HIV and HCV negative haemophiliacs treated with intermediate-purity factor VIII concentrates.
    Funk M; Ebener U; Kreuz W; Ehrenforth S
    Lancet; 1993 Oct; 342(8876):933-4. PubMed ID: 7692198
    [No Abstract]   [Full Text] [Related]  

  • 8. Hemophilia A and von Willebrand deficiency: therapeutic implications.
    Basso M; Lazzareschi I; Curatola A; Di Gennaro L; Buonsenso D; Gatto A; De Candia E; De Cristofaro R
    Blood Coagul Fibrinolysis; 2020 Sep; 31(6):397-401. PubMed ID: 32255574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C and pasteurised factor VIII and IX concentrates.
    Klarmann D; Kreuz W; Auerswald G; Auberger K; Rabenau H; Gürtler L; Roggendorf M
    Thromb Haemost; 1995 Apr; 73(4):736-7. PubMed ID: 7495095
    [No Abstract]   [Full Text] [Related]  

  • 10. [Efficacy in viral inactivation of the concentrates of factor VIII and IX by the solvent/detergent procedure. Evaluation in patients with hemophilia].
    Guerois C; Parquet A; Vicariot M; Lecoeur FF; Maisonneuve P; Courouce AM; Dubois F; Laurian Y
    Presse Med; 1991 Jun; 20(25):1163-6. PubMed ID: 1830653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of haemophilia A and v. Willebrand's disease.
    Nilsson IM
    Bibl Haematol; 1965; 23():1307-12. PubMed ID: 5296087
    [No Abstract]   [Full Text] [Related]  

  • 12. The management of haemophilia A with concentrated preparations of factor VIII.
    Castaldi PA; Somer JB; Schiff P; Blackburn CR
    Bibl Haematol; 1968; 29():1166. PubMed ID: 5303859
    [No Abstract]   [Full Text] [Related]  

  • 13. Correction by factor VIII of decreased neutrophil alkaline phosphatase activity in classic haemophilia and von Willebrand's disease.
    Janković GM
    Thromb Res; 1979; 16(3-4):557-64. PubMed ID: 316208
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80: report on behalf of the directors of haemophilia centres in the United Kingdom.
    Rizza CR; Spooner RJ
    Br Med J (Clin Res Ed); 1983 Mar; 286(6369):929-33. PubMed ID: 6403138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Von Willebrand factor in high-purity factor VIII complex concentrates: chaperone protein or key to therapies? A meeting report.
    Federici AB; Mannucci PM; Marco P
    Haemophilia; 2008 Jan; 14(1):133-9. PubMed ID: 17941830
    [No Abstract]   [Full Text] [Related]  

  • 16. From the Centers for Disease Control and Prevention. Hepatitis A among persons with hemophilia who received clotting factor concentrate--United States, September-December 1995.
    JAMA; 1996 Feb; 275(6):427-8. PubMed ID: 8627951
    [No Abstract]   [Full Text] [Related]  

  • 17. Correction by factor VIII of decreased neutrophil alkaline phosphatase activity in classic haemophilia and von Willebrand's disease.
    Janković GM; Janosević S
    Haematologia (Budap); 1978-1979; 12(1-4):183-8. PubMed ID: 317061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of various factor VIII concentrates used in treatment of haemophilia A.
    Nilsson IM; Hedner U
    Br J Haematol; 1977 Dec; 37(4):543-57. PubMed ID: 304740
    [No Abstract]   [Full Text] [Related]  

  • 19. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
    Brinkhous KM
    Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of hepatitis C virus infection in haemophiliacs.
    Lancet; 1990 Jun; 335(8703):1473-4. PubMed ID: 1972253
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.